Targeted and immuno-therapy to overcome innate and acquired resistance in aggressive MAPK-addicted cancers.

靶向和免疫治疗可克服侵袭性 MAPK 成瘾癌症的先天性和获得性耐药性。

• 批准号: 469037
• 负责人: Nichols Anthony C
• 金额: $ 72.17万
• 依托单位: University of Western Ontario
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-09-01 至 2027-09-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=469037&lang=en
• 关键词: Anaplastic Thyroid Cancer; Braf Mutation; Immunotherapy; Single Cell Sequencing; Syngeneic Mouse Models; Targeted Therapy; Thyroid Cancer; Whole Genome Sequecing

Thyroid cancer is one of the fastest rising cancers in Canada. Most thyroid cancers are non-aggressive types and are almost always cured with surgery. In contrast, anaplastic thyroid cancer (ATC) accounts for only 1% of thyroid cancers but is perhaps the

甲状腺癌是加拿大发病率最快的癌症之一。大多数甲状腺癌是非侵袭性类型，几乎总是可以通过手术治愈。相比之下，甲状腺未分化癌 (ATC) 仅占甲状腺癌的 1%，但可能是最常见的甲状腺癌。